The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Open accessAbstract
BACKGROUND: Approximately 75% of objective responses to anti-programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years, but delayed relapses have been noted long after initial objective tumor regression despite continuous therapy. Mechanisms of immune escape in this context are unknown. METHODS: We analyzed biopsy samples from paired baseline and relapsing lesions in four patients with metastatic melanoma who had had an initial objective tumor regression in response to anti-PD-1 therapy (pembrolizumab) followed by disease progression months to years later. RESULTS: Whole-exome sequencing detected clonal selection and outgrowth of the acquired resistant tumors and, in two of the four patients, revealed resistance-associated loss-of-function mutations in the genes encoding interferon-receptor-associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), concurrent with deletion of the wild-type allele. A truncating mutation in the gene encoding the antigen-presenting protein beta-2-microglobulin (B2M) was identified in a third patient. JAK1 and JAK2 truncating mutations resulted in a lack of response to interferon gamma, including insensitivity to its antiproliferative effects on cancer cells. The B2M truncating mutation led to loss of surface expression of major histocompatibility complex class I. CONCLUSIONS: In this study, acquired resistance to PD-1 blockade immunotherapy in patients with melanoma was associated with defects in the pathways involved in interferon-receptor signaling and in antigen presentation. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinically relevant mechanisms of include mutations in beta-2-microglobulin (B2M) resulting in loss of MHC Class I presentation, downregulation of the antigen presentation machinery, and mutations in the IFNγ-JAK/STAT pathway that impair response to T cell mediated anti-tumor activity7–9.”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [7]
In the citing paper
“perturbations of B2M, HLA-A, JAK1, JAK2, STAT1, IFNGR1 and IFNGR2 (Fig. 2d,e, Extended Data Fig. 3e,f, Supplementary Table 2) conferred immune evasion, consistent with clinical mechanisms of resistance to immunotherapy7–9.”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [7]
In the citing paper
“These findings are consistent with emerging clinical data correlating resistance to checkpoint inhibitors with mutations in the B2m and IFNγ pathways (Gao et al., 2016; Zaretsky et al., 2016), and with recent genome-wide CRISPR screening data (Patel et al., 2017).”
From Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens (2018) · cites this paper as Zaretsky et al., 2016
In the citing paper
“Mutations in IFNGR1 and JAK, a component of the IFNγ signaling pathway, have been found in patients presenting resistance to checkpoint inhibitors (Gao et al., 2016; Zaretsky et al., 2016).”
From Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens (2018) · cites this paper as Zaretsky et al., 2016
In the citing paper
“Tumor cells may evade immune recognition directly by downregulating features that make them vulnerable such as tumor antigens or MHC class I (4–6).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [6]
In the citing paper
“Tumors in patients treated with anti-PD-1 who initially responded and then relapsed showed mutations that caused a subsequent loss in MHC class I surface expression (to avoid cytotoxic T cell recognition) or in IFN-γ response elements (6).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [6]
In the citing paper
“Tumor cells from patients refractory to anti-PD-1 treatment, for example, were recently shown to have acquired mutations making them less susceptible to T cell-mediated killing via loss of IFN-γ response elements or MHC class I (6).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [6]
In the citing paper
“Consistent with the preclinical data, patients with melanoma harboring genomic defects in IFNγ pathway genes did not respond to anti-CTLA4 (160).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [160]
In the citing paper
“In the same study, tumor cells in another patient demonstrating relapse contained a frameshift deletion of β 2 -microglobulin (B2M), disrupting MHC I trafficking to the cell surface and thereby rendering the tumor cells invisible to cytotoxic CD8 + T cells (110).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Circos: An information aesthetic for comparative genomicsPreprint
Krzywinski, M. I., Schein, J. E., Birol, İ., Connors, J. M., Gascoyne, R. D., Horsman, D. E., Jones, S. J. M., & Marra, M. A. (2009) · Genome Research · doi:10.1101/gr.092759.109 · Cited by 11,029
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Flagged first, then by citations
Research works printed but not linked: 2
- Atkins MB, 2000, Cancer J Sci Am, 6, S11
- Finke JH, 1993, Cancer Res, 53, 5613
Cited by
Sorted by citations
Items 101–134 of 134
A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma
Pozniak, J., Pedri, D., Landeloos, E., Van Herck, Y., Antoranz, A., Vanwynsberghe, L., Nowosad, A., Roda, N., Makhzami, S., Bervoets, G., et al. (2024) · Cell · doi:10.1016/j.cell.2023.11.037 · Cited by 199
Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies
Roth, T. L., Li, P. J., Blaeschke, F., Nies, J. F., Apathy, R., Mowery, C., Yu, R., Nguyen, M. L. T., Lee, Y., Truong, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.039 · Cited by 186
Immunological Mechanisms Underneath the Efficacy of Cancer Therapy
Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0197 · Cited by 175
Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens
Wroblewska, A., Dhainaut, M., Ben-Zvi, B., Rose, S. A., Park, E. S., Amir, E.-A. D., Bektesevic, A., Baccarini, A., Merad, M., Rahman, A. H., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.022 · Cited by 168
IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
Thiem, A., Hesbacher, S., Kneitz, H., di Primio, T., Heppt, M. V., Hermanns, H. M., Goebeler, M., Meierjohann, S., Houben, R., & Schrama, D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1403-9 · Cited by 153
Trujillo, J. A., Luke, J. J., Zha, Y., Segal, J. P., Ritterhouse, L. L., Spranger, S., Matijevich, K., & Gajewski, T. F. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0780-0 · Cited by 159
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Torrejon, D. Y., Abril-Rodriguez, G., Champhekar, A. S., Tsoi, J., Campbell, K. M., Kalbasi, A., Parisi, G., Zaretsky, J. M., Garcia-Diaz, A., Puig-Saus, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1409 · Cited by 146
Self-citationUnderstanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., & Zhou, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01237 · Cited by 153
Pai, C.-C. S., Huang, J. T., Lu, X., Simons, D. M., Park, C., Chang, A., Tamaki, W., Liu, E., Roybal, K. T., Seagal, J., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.006 · Cited by 141
FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells
Shen, J. Z., Qiu, Z., Wu, Q., Finlay, D., Garcia, G., Sun, D., Rantala, J., Barshop, W., Hope, J. L., Gimple, R. C., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.042 · Cited by 113
Bai, X., Fisher, D. E., & Flaherty, K. T. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0204-6 · Cited by 107
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy
Anderson, P., Aptsiauri, N., Ruiz-Cabello, F., & Garrido, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00634-7 · Cited by 107
The role of biomarkers in personalized immunotherapy
Sankar, K., Ye, J. C., Li, Z., Zheng, L., Song, W., & Hu-Lieskovan, S. (2022) · Biomarker Research · doi:10.1186/s40364-022-00378-0 · Cited by 111
Self-citationTGF‐β–responsive CAR‐T cells promote anti‐tumor immune function
Hou, A. J., Chang, Z. L., Lorenzini, M. H., Zah, E., & Chen, Y. Y. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10097 · Cited by 106
The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy
Paucek, R. D., Baltimore, D., & Li, G. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.002 · Cited by 104
Huang, L., Malu, S., McKenzie, J. A., Andrews, M. C., Talukder, A. H., Tieu, T., Karpinets, T., Haymaker, C., Forget, M.-A., Williams, L. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2483 · Cited by 102
Self-citationAffinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor
Peled, M., Tocheva, A. S., Sandigursky, S., Nayak, S., Philips, E. A., Nichols, K. E., Strazza, M., Azoulay-Alfaguter, I., Askenazi, M., Neel, B. G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710437115 · Cited by 87
Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92
Regulatory mechanisms of PD-L1 expression in cancer cells
Shi, Y. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2226-9 · Cited by 92
Marijt, K. A., Sluijter, M., Blijleven, L., Tolmeijer, S. H., Scheeren, F. A., van der Burg, S. H., & van Hall, T. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0627-8 · Cited by 85
Ahronian, L. G., & Corcoran, R. B. (2017) · Genome Medicine · doi:10.1186/s13073-017-0431-3 · Cited by 67
Randrian, V., Evrard, C., & Tougeron, D. (2021) · Cancers · doi:10.3390/cancers13123063 · Cited by 65
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
D’Angelo, S. P., Richards, A. L., Conley, A. P., Woo, H. J., Dickson, M. A., Gounder, M., Kelly, C., Keohan, M. L., Movva, S., Thornton, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30874-8 · Cited by 60
Slama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., & Gasque, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713511 · Cited by 57
Checkpoint immunotherapy in pediatrics: here, gone, and back again
Long, A. H., Morgenstern, D. A., Leruste, A., Bourdeaut, F., & Davis, K. L. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349799 · Cited by 53
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Giricz, O., Mo, Y., Dahlman, K. B., Cotto-Rios, X. M., Vardabasso, C., Nguyen, H., Matusow, B., Bartenstein, M., Polishchuk, V., Johnson, D. B., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120422 · Cited by 40
Epigenetic mechanisms of tumor resistance to immunotherapy
Arenas-Ramirez, N., Sahin, D., & Boyman, O. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2908-7 · Cited by 36
Jamal, R., Messaoudene, M., de Figuieredo, M., & Routy, B. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101754 · Cited by 31
Zhuo, N., Liu, C., Zhang, Q., Li, J., Zhang, X., Gong, J., Lu, M., Peng, Z., Zhou, J., Wang, X., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.4637 · Cited by 30
Mitra, A., Andrews, M. C., Roh, W., De Macedo, M. P., Hudgens, C. W., Carapeto, F., Singh, S., Reuben, A., Wang, F., Mao, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15538-9 · Cited by 27
Snahnicanova, Z., Kasubova, I., Kalman, M., Grendar, M., Mikolajcik, P., Gabonova, E., Laca, L., Caprnda, M., Rodrigo, L., Ciccocioppo, R., et al. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00601-7 · Cited by 29
Ye, Q., Zhou, X., Ren, H., Han, F., Lin, R., & Li, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274336 · Cited by 15
Samnani, S., Sachedina, F., Gupta, M., Guo, E., & Navani, V. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.02 · Cited by 12
Metadata
- Authors
- Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., Saco, J., Homet Moreno, B., Mezzadra, R., Chmielowski, B., Ruchalski, K., Shintaku, I. P., Sanchez, P. J., Puig-Saus, C., Cherry, G., Seja, E., Kong, X., Pang, J., Berent-Maoz, B., Comin-Anduix, B., Graeber, T. G., Tumeh, P. C., Schumacher, T. N. M., Lo, R. S., & Ribas, A.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-09
- Volume
- 375
- Issue
- 9
- Pages
- 819-829
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5007206
- OpenAlex
- W2465860350
- Cited by
- 3,237
- References
- 39
- Citations by year
- 2026: 272 · 2025: 239 · 2024: 248 · 2023: 317 · 2022: 351 · 2021: 413 · 2020: 381 · 2019: 305 · 2018: 338 · 2017: 323 · 2016: 45
- FWCI
- 181.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Association for Cancer Research (5T32AR058921-05, 5T32CA009120-39, SU2C-AACR-DT1012, 5T32CA009297-30)
- Cancer Research Institute (SU2C-AACR-DT1012)
- American Skin Association
- Melanoma Research Alliance (SU2C-AACR-DT1012, 20120279)
- Entertainment Industry Foundation
- University of Chicago
- Tower Cancer Research Foundation (5T32CA009297-30, 5T32CA009120-39, 5T32AR058921-05)
- Hope Foundation
- National Institutes of Health (UL1TR000124, 5t32ar058921-04, SU2C-AACR-DT1012, CA199090, CA197633, UL1TR001881)
- Stand Up To Cancer (5T32CA009297-30, SU2C-AACR-DT1012), 5T32AR058921-05, 5T32CA009120-39)
- National Cancer Institute (P01CA168585, U54CA199090, R01CA170689, T32CA009297, T32CA009120, R35CA197633, P30CA016042)
- National Institute of General Medical Sciences (GM-08042, T32GM008042)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (5T32AR058921-05, T32-AR058921)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- acquired resistance, anti-PD-1 therapy, melanoma, pembrolizumab, JAK1 mutations, JAK2 mutation, beta2-microglobulin, interferon-gamma signaling, MHC class I loss, clonal selection, immune evasion, tumor recurrence, immunotherapy resistance
- MeSH terms
- Antineoplastic Agents, beta 2-Microglobulin, Biopsy, Genes, MHC Class I, Humans, Immunotherapy, Interferon-gamma, Melanoma, Mutation, Recurrence, Signal Transduction, Gene Expression Regulation, Neoplastic, Sequence Analysis, DNA, Drug Resistance, Neoplasm, Janus Kinase 1, Janus Kinase 2, Exome, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
